Shandong Pharmaceutical Glass Co. (600529) Fair Value & Analysis
Consumer Cyclical · CN · Market cap 12.1B CNY
Analysis
Shandong Pharmaceutical Glass Co. (600529) currently trades at ¥18.70, while our model-based Fair Value estimate is ¥22.80 — implying the stock looks roughly 21.9% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Shandong Pharmaceutical Glass Co.Ltd engages in research and development, production, and sale of various pharmaceutical glass packaging products in China. The company offers moulded glass products, including amber glass containers, dropper bottles, infusion bottles, cosmetic bottles, tablet bottle, food glass, cobalt blue and green bottles, and black bottles, as well as moulded glass injection vial comprising type I/II/III. It also provides tubular glass products, such as glass tubes for pharma use, other tubular bottle with screw neck finish, PFS and glass cartridges, tubular glass vials for injection, and ampoules. In addition, the company offers closures for glass containers comprising plastic bottles, dropper cap, plastic cap for bottles, plunger and combiseal for glass cartridge, teflon coated rubber stopper, rubber stopper for injection vial/bottle, accessories for PFS, and flip off cap and Al-seal. Further, it provides butyl rubber stopper for injection; and prefilled syring…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.